Elisa Cascade, CPO of Science 37: A Fervent Leader with Over Three Decades of Experience in Advancing Clinical Trial Technology, Carving a New Path to Drive the Future of Clinical Research

Decentralization of clinical trials has been a growing topic of discussion and development over the last few years, enabled further by the advancement of available technologies. A new approach to clinical research is certainly needed. Increased decentralization of trial elements is just one way – albeit a hugely important one – that patient needs can not only be put first within the clinical trial journey but be used to shape its processes and policies. As more clinical trials adopt decentralized elements successfully and technology advances even further, the number of home-based trials is going to increase – and along with this, so will participants’ expectations. Decentralization' primary goal is to make clinical trial participation as easy as possible, and enabling participants to continue with their day-to-day lives with minimal disruption.

Science 37 is one such company that is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based models. They have proven to enroll faster, retain patients at a higher rate, and reach a more representative population. Science 37 has conducted more decentralized, interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses, who are supported by the industry’s most comprehensive, fully integrated, decentralized clinical trial platform.

Accelerating Decentralized Clinical Trials with Unified Technology

The Agile Clinical Trial™: No two trials are the same. That’s why Science 37 delivers the Agile Clinical Trial – a multi-modal hybrid offering that supports any study. It is a multi-modal approach to research encompassing decentralized, on-site, or the full spectrum of hybrid clinical trials—delivering flexibility to add traditional and non-traditional elements into the mix as an extension to trial design. The platform offers a global, scalable and configurable end-to-end clinical trial SaaS platform that powers decentralized clinical trials. From Telemedicine and eConsent, to eCOA/ePRO and eSource, and the unified technology platform supports sponsors and CROs at all stages. Seamlessly navigate Agile (hybrid) Clinical Trials with centralized networks- allowing patients to be recruited, enrolled and seen from anywhere. Science 37's networks include patient communities, mobile nursing, remote coordinators, community providers and data and devices. Whether adding to an original site, an EDC, or using for a long-term follow-up post clinical trial - virtual sites can be added to any Agile (hybrid) Clinical Trial at any stage.

Metasite™: Accelerate patient recruitment, enrollment and retention while increasing diversity with the Science 37 Operating System™ that powers decentralized clinical trials. Eliminate barriers with the Science 37 Metasite - a virtual site that allows patients and providers access, no matter their geographic location. By supplementing a brick-and-mortar site strategy, the Metasite expands reach beyond traditional sites - expediting recruitment, advancing retention, improving data quality, and enhancing the patient experience- all while delivering a more diverse patient population to clinical trials. Before virtual sites, traveling to a brick-and-mortar site excluded many patients from participating in clinical trials. With the Metasite or Metasite Rescue, any patient & any provider can access clinical trials - accelerating enrollment, improving data quality and delivering a more diverse population - ultimately bringing breakthrough treatments to market. With a Metasite (virtual site), patients can be seen at both traditional sites and in the comfort of their own homes with broadly-licensed telemedicine physicians, in-house mobile healthcare providers and research coordinators.

Operating System™: With the Science 37 Operating System, you can recruit any patient or provider —which accelerates recruitment, improves data quality, and delivers a more representative population—ultimately bringing breakthrough treatments to market. The Science 37 OS delivers an Agile Clinical Trial™ that fits the unique needs of your study— while allowing patients to be seen in the comfort of their own home or by a local provider. Quality providers work seamlessly with Science 37’s technology platform to help operationalize, conduct, and support increasingly complex hybrid and decentralized clinical trial designs both at-home and on-site within local communities. Accelerate your trial with multi-channel patient access, including Science 37’s registry of 500k+ patients. Attract, enroll and retain more participants beyond the traditional site delivering real-world representation.

Elisa Cascade | Chief Product Officer

Elisa Cascade has devoted more than 30 years to advancing clinical trial technology, direct-to-patient operations, and healthcare strategy. Throughout her career, she has been instrumental in using technology to transform clinical research to better serve all industry stakeholders. Before joining Science 37 as chief product officer, Elisa held a number of high-profile roles, including executive VP and product line executive for eCOA at ERT; chief product officer at DrugDev, an IQVIA Company; and VP of the digital patient unit at Quintiles. As an esteemed industry veteran, Elisa adds tremendous technological expertise and strategic prowess to Science 37’s Operating System, helping the company achieve its mission of enabling universal access to clinical trials—resulting in accelerated timelines, reduced patient burden, increased retention, and more representative participants. Elisa earned an MBA at The Wharton School of the University of Pennsylvania.

"We make clinical research more accessible to underserved populations to enable faster enrollment, better retention and more representatives of real-world populations."